Nanjing Hicin Pharmaceutical Co Ltd (SHE:300584) — Market Cap & Net Worth
Market Cap & Net Worth: Nanjing Hicin Pharmaceutical Co Ltd (300584)
Nanjing Hicin Pharmaceutical Co Ltd (SHE:300584) has a market capitalization of $588.60 Million (CN¥4.02 Billion) as of October 11, 2026. Listed on the SHE stock exchange, this China-based company holds position #11439 globally and #3257 in its home market, demonstrating a 7.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanjing Hicin Pharmaceutical Co Ltd's stock price CN¥33.52 by its total outstanding shares 120000000 (120.00 Million).
Nanjing Hicin Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Nanjing Hicin Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $364.64 Million to $588.60 Million (13.03% CAGR). Check latest Nanjing Hicin Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Nanjing Hicin Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanjing Hicin Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Nanjing Hicin Pharmaceutical Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.31x
Nanjing Hicin Pharmaceutical Co Ltd's market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20.97x
Nanjing Hicin Pharmaceutical Co Ltd's market cap is 20.97 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $364.64 Million | $455.03 Million | $65.60 Million | 0.80x | 5.56x |
| 2018 | $408.93 Million | $711.91 Million | $83.22 Million | 0.57x | 4.91x |
| 2019 | $481.15 Million | $924.54 Million | $97.26 Million | 0.52x | 4.95x |
| 2020 | $354.23 Million | $706.30 Million | $55.23 Million | 0.50x | 6.41x |
| 2021 | $347.53 Million | $578.32 Million | $285.88 Million | 0.60x | 1.22x |
| 2022 | $563.61 Million | $526.47 Million | $32.45 Million | 1.07x | 17.37x |
| 2023 | $407.48 Million | $517.83 Million | $36.32 Million | 0.79x | 11.22x |
| 2024 | $354.01 Million | $504.36 Million | $40.22 Million | 0.70x | 8.80x |
| 2025 | $881.85 Million | $671.05 Million | $42.06 Million | 1.31x | 20.97x |
Competitor Companies of 300584 by Market Capitalization
Companies near Nanjing Hicin Pharmaceutical Co Ltd in the global market cap rankings as of October 11, 2026. See Nanjing Hicin Pharmaceutical Co Ltd balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Nanjing Hicin Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
Nanjing Hicin Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Nanjing Hicin Pharmaceutical Co Ltd's market cap moved from $364.64 Million to $ 588.60 Million, with a yearly change of 13.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥588.60 Million | -33.25% |
| 2025 | CN¥881.85 Million | +149.11% |
| 2024 | CN¥354.01 Million | -13.12% |
| 2023 | CN¥407.48 Million | -27.70% |
| 2022 | CN¥563.61 Million | +62.18% |
| 2021 | CN¥347.53 Million | -1.89% |
| 2020 | CN¥354.23 Million | -26.38% |
| 2019 | CN¥481.15 Million | +17.66% |
| 2018 | CN¥408.93 Million | +12.15% |
| 2017 | CN¥364.64 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Nanjing Hicin Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $588.60 Million USD |
| MoneyControl | $588.60 Million USD |
| MarketWatch | $588.60 Million USD |
| marketcap.company | $588.60 Million USD |
| Reuters | $588.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more